Back to results
US 8,575,137 B2Granted
Composition for inhalation
AssigneeAstraZeneca AB
InventorsNayna Govind, Maria Marlow
Life of this patent
Estimating the term…
Abstract
The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
Claims53
A pharmaceutical suspension composition comprising formoterol fumarate dihydrate;
- budesonide;
- 1,1,1,2,3,3,3-heptafluoropropane (HFA227);
- polyvinyl pyrrolidone (PVP);
- and polyethylene glycol (PEG), wherein the budesonide is present in the composition at a concentration in the range of 1 mg/ml to 8 mg/ml, the PVP is present at a concentration in the range of 0.001% to 0.01% w/w, and the PEG is present at a concentration in the range of 0.05 to 0.5% w/w.
1 more element
A pharmaceutical suspension composition comprising formoterol fumarate dihydrate, budesonide, HFA227, PVP K25, and PEG-1000, wherein the budesonide is present at a concentration in the range of 1 mg/ml to 8 mg/ml and the PVP K25 is present at a concentration of 0.001% w/w.
Dependencies are inferred from the claim text.